TNFRSF6B and neoplasm: Due to the lack of transmembrane domain, DcR3 disturbs the binding of these receptors to ligands through competitive inhibition, while it also conducts the signaling pathways for tumor cell growth, invasion and epithelial-mesenchymal transition (EMT) (85, 86).